Services Pharmacogenotyping

 

HLAB*15:02 genotyping

iPROMISE has developed a genotyping test kit for the detection of HLAB*15:02 variant, which has a high association with Steven-Johnson Syndrome (SJS) / toxic epidermal necrolysis (TEN). The Food and Drug Administration (FDA, USA) recommends that individuals of Asian ancestry be genotyped for the presence of the HLA-B*1502 variant prior to receiving carbamazepine or phenytoin to avoid adverse drug reactions.

*we are currently in the process of applying for ISO 15189

 

Other genotyping services

VKORC1 : Warfarin resistance and sensitive
HLAB*5801 : Allopurinol hypersensitivity
CYP2D6 : Ultra-rapid and poor metaboliser of antipsychotic drugs
CYP2C19 : Clopidogrel resistance
DPYD : 5-FU toxicity
TPMT : 6-mercaptopurine toxicity
UGT1A1 : Irinotecan toxicity
CYP3A5 : Tacrolimus toxicity
CYP2C9 : Warfarin and NSAIDs toxicity

 

 


 


Inquiry / Request a quotation.

Please contact our technical officer at : 
ipromise[dot]uitm[at]gmail[dot]com
Tel : +603-3258 4652
Fax : +603-3258 4658

 

 

Go to top
JSN Boot template designed by JoomlaShine.com